FreeCME

Clinical Consultations™: SARS-CoV-2 Vaccination in Patients with MS – What Clinicians Need to Know Now

CME: 1.25

Program Overview

This Clinical ConsultationsTM is a video-based program in which two experts discuss the management of patients with multiple sclerosis (MS) and SARS-CoV-2 vaccinations. In this activity, the faculty focus on the effects of disease modifying therapies (DMTs) on vaccine practices, specifically the mRNA vaccines for SARS-CoV-2. This engaging format is designed to help clinicians identify best practices in the management of patients with MS and to improve outcomes for their patients with this disease in the era of COVID-19.

There are over a dozen FDA-approved DMTs to treat patients with MS. These therapies have various effects on humoral and cellular immunity, which are the key components in the protective immune response generated by vaccinations. In the midst of the COVID-19 pandemic, several mRNA-based vaccines for SARS-CoV-2 have been developed. Their effectiveness is based in part on the cell-mediated adaptive immune response. It is this cell-mediated response to vaccines that is of particular importance to clinicians who manage patients with MS, as patients who are treated with DMTs face challenges with respect to the interaction between DMTs that affect the humoral immune response and vaccines in general.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Discuss the effects of vaccines on the immune response
  • Outline the mechanisms of action of vaccines targeting SARS-CoV-2
  • Describe the impact of disease modifying therapies used in the management of MS on response to vaccines
  • Incorporate evidence-based SARS-CoV-2 vaccination strategies into disease management plans for patients with MS

Post a comment to this article